CAS 603139-19-1

Odanacatib

Description:

Odanacatib is a small molecule inhibitor that specifically targets cathepsin K, an enzyme involved in bone resorption. It is primarily investigated for its potential use in treating osteoporosis and other bone-related disorders by reducing bone loss and increasing bone density. Odanacatib is characterized by its selective inhibition of cathepsin K, which plays a crucial role in the breakdown of bone tissue. The compound has a relatively long half-life, allowing for less frequent dosing compared to other osteoporosis treatments. Its mechanism of action involves the inhibition of osteoclast activity, which are the cells responsible for bone resorption. Odanacatib has undergone various clinical trials to assess its efficacy and safety profile, showing promise in improving bone mineral density in postmenopausal women. However, its development has faced scrutiny regarding potential cardiovascular risks, leading to a reevaluation of its therapeutic use. Overall, Odanacatib represents a novel approach in the management of osteoporosis, focusing on the inhibition of specific pathways involved in bone metabolism.

Formula: C₂₅H₂₇F₄N₃O₃S

InChI: InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1

InChI key: InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N

SMILES: N(C([C@@H](N[C@H]([C@](F)(F)F)C1=CC=C(C=C1)C2=CC=C(S(C)(=O)=O)C=C2)CC(C)(C)F)=O)C3(C#N)CC3

Synonyms:

• (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide
• N¹-[(1-Cyanocyclopropyl)-4-fluoro-N²-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-<span class="text-smallcaps">L</span>-leucinamide
• Odanacatib
• MK 0822
• N1-[(1-Cyanocyclopropyl)-4-fluoro-N2-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-L-leucinamide
• Pentanamide, N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]-, (2S)-

Odanacatib

CAS: 603139-19-1

Formula: C₂₅H₂₇F₄N₃O₃S

Purity: 98%

Color and Shape: Solid

Molecular weight: 525.5588

Ref: IN-DA0039T3

Odanacatib

CAS: 603139-19-1

Odanacatib

Purity: ≥98%

Molecular weight: 525.56g/mol

Ref: 54-BUP04942

Odanacatib

CAS: 603139-19-1

Odanacatib is an inhibitor of cathepsin K with potential anti-osteoporotic activity.

Formula: C₂₅H₂₇F₄N₃O₃S

Purity: 98.53% - 99.53%

Color and Shape: Solid

Molecular weight: 525.56

Ref: TM-T6035

MK-0822

Controlled Product

CAS: 603139-19-1

Applications MK-0822 is a newly developed bone-targeting dual action pro-drug for osteoporosis and bone metastasis. It is also an inhibitor of cathepsin K, an enzyme involved in bone resorption.
References Arns, S., et al.: Bioorg. Medn. Chem., 20, 2131 (2012); Cusick, T., et al., J. Bone. Mineral. Rsch., 27, 524 (2013);

Formula: C₂₅H₂₇F₄N₃O₃S

Color and Shape: Off-White

Molecular weight: 525.5588

Ref: TR-M425015

MK 0822

CAS: 603139-19-1

Inhibitor of cathepsin K inhibitor; reduces bone resorption

Formula: C₂₅H₂₇F₄N₃O₃S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 525.56 g/mol

Ref: 3D-FM65088